Prolyl hydroxylase domain
From Proteopedia
| |||||||||||
3D Structures of prolyl hydroxylase domain
2y33 – hPHD2 + Zn + quinolin derivative – human
3ouh, 3oui, 5v18 - hPHD2 + Fe + inhibitor
4kbz - hPHD2 (mutant) + Fe + inhibitor
5a3u - hPHD2 + Mn + inhibitor
4jzr - hPHD2 + Ni + inhibitor
3ouj - hPHD2 + Fe + 2OG
5l9r - hPHD2 (mutant) + Mn + 2OG
3hqr, 5l9b - hPHD2 (mutant) + Mn + HIF 1 α C terminal + 2OG
5l9v, 5la9, 5las - hPHD2 (mutant) + Mn + HIF NODD domain + 2OG
3hqu - hPHD2 + Fe + HIF 1 α C terminal + quinolin derivative
2hbt, 2hbu, 2g19, 2g1m, 2y34, 4bqi - hPHD2 + Fe + quinolin derivative
4bqw, 4bqx, 4bqy - hPHD2 + Mn + quinolin derivative
5lat, 5lb6, 5lbb, 5lbc, 5lbe, 5lbf, 4uwd - hPHD2 (mutant) + Mn + quinolin derivative
4h6j – hPHD Pasb domain (mutant) + aryl hydrocarbon nuclear translocator (mutant)
5v1b - hPHD1 + Fe + inhibitor
References
- ↑ Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp. 2006;272:15-25; discussion 25-36. PMID:16686427
- ↑ Rosen M D, Venkatesan H, Peltier H M, Bembenek S D, Kanelakis K C, Zhao L X, Leonard B E, Hocutt F M, Wu X, Palomino H L, Brondtetter T I, Haugh P V, Cagnon L, Yan W, Liotta L A, Young A, Mirzadegan T, Shankley N P, Barrett T D, Rabinowitz M H. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues. ACS Medicinal Chemical Letters. 2010 Oct 5.
Created with the participation of Andrew Winslow.

